Epredia, a global leader in precision cancer diagnostics and subsidiary of PHC Holdings Corporation and NovaScan, Inc., a company that develops breakthrough technology for cancer detection and stratification, announce that they have signed a letter of intent for a U.S. exclusive commercial distribution agreement for MarginScan™, a medical device that will support physicians in real-time detection of non-melanoma skin cancer. Epredia has engaged Avantik, a company specializing in supporting diagnostic labs with their operations, with getting this new device into the hands of Mohs surgeons.
MarginScan™ is designed to address this challenge by supporting Mohs surgery procedures for skin cancer treatment. Mohs Micrographic Surgery (MMS) is an operative method used to detect the presence or absence of a tumor in the margins of a surgical excision. In an MMS procedure, cancer tissue is excised in stages, then flash-frozen and assessed histologically in an onsite lab until clean margins are obtained. Previously, MMS was the only modality for skin cancer treatment that involved comprehensive margin assessment during a procedure. MarginScan™ is designed to use an electrical assessment to confirm cancer-free margins without the intraoperative histological assessment. This has the potential to allow for faster excisions that spare more healthy tissue, leading to improved outcomes for both patients and clinicians.
With this planned agreement, Epredia will serve as the primary distribution partner of MarginScan™ and will have exclusive distribution rights in the United States. Along with distribution, Epredia will be responsible for all marketing and commercial activities related to the launch and sale of MarginScan™. Epredia will work closely with Avantik to market and sell the new device to Mohs surgeons.
MarginScan™ will be the latest addition to Epredia’s world-class portfolio of precision cancer diagnostics products and services that provide a seamless end-to-end laboratory workflow, including slide scanners and printers, cryostats, tissue processors, and consumables such as slides and reagents. In addition to offering MarginScan™, Epredia will also provide consumable products that are used with the device, such as the MarginScan™ electrode and proprietary electrolytic gel used during excisions.
The two companies anticipate a 2025 U.S. launch for MarginScan™. This distribution agreement builds on a previous partnership between NovaScan and PHC Corporation, another subsidiary of PHC Holdings Corporation that is focused on the development and manufacturing of innovative medical testing devices. PHC Holdings Corporation is referred to collectively with its subsidiaries as PHC Group.
Steven Lynum, President of Epredia, said, “With more than 85 years supporting precision cancer diagnostics, we strive to continuously serve the changing needs of our customers by working with innovative companies like NovaScan to deliver the best solutions. Helping providers make faster, more accurate diagnoses and ultimately improving patient care is what makes this initiative so important.”
Craig Davis, CEO of NovaScan, remarked, “NovaScan is thrilled to be partnering with Epredia to bring MarginScan™ to clinical healthcare providers in the U.S. We are proud for MarginScan™ to join Epredia’s portfolio of market-leading cancer diagnostics products. We believe that MarginScan™ will play an important role in skin cancer detection and treatment.”
Mark Zacur, CEO of Avantik, added, “Our team is continually sourcing the best solutions to expand our portfolio of solutions supporting Mohs clinics with their critical work. We are honored that Epredia selected Avantik as their partner to bring this breakthrough device to our network of providers and their patients.”
SOURCE: Businesswire